Global Postmenopausal Osteoporosis Drugs Market 2016-2020

  • ID: 3723302
  • Report
  • Region: Global
  • 60 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • Deltanoid Pharmaceuticals
  • Novartis
  • Osteologix
  • Radius Health
  • Uni-Bio Science Group
  • MORE
About the Postmenopausal Osteoporosis Drugs Market

Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.

Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.

The analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Eli Lilly
- Amgen
- Merck
- Novartis

Other prominent vendors
- Allergan
- Amgen Astellas Biopharm
- Deltanoid Pharmaceuticals
- Noven
- Novo Nordisk
- Osteologix
- Pfizer
- PhytoHealth
- Radius Health
- Tarsa Therapeutics
- UCB
- Uni-Bio Science Group
- Upsher-Smith Laboratories
- Watson Pharmaceuticals
- Zosano Pharma

Market drivers
- Growing prevalence of postmenopausal osteoporosis

Market challenges
- Low diagnosis rate

Market trends
- Emergence of novel agents

Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • Deltanoid Pharmaceuticals
  • Novartis
  • Osteologix
  • Radius Health
  • Uni-Bio Science Group
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Understanding postmenopausal osteoporosis
  • Epidemiology and demography
  • Risk factors
  • Symptoms
  • Diagnosis
  • Treatment
PART 06: Key buying criteria

PART 07: Pipeline scenario
  • TBRIA
  • Romosozumab (AMG785)
  • Odanacatib (MK-0822)
  • Abaloparatide SC/Abaloparatide transdermal patch
  • PHN-031 (PH3)
  • NB S101
  • Teriparatide ZP Patch (ZP-PTH)
  • Blosozumab (LY2541546)
PART 08: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 09: Market segmentation by therapeutic class
  • Antiresorptive medications
  • Anabolic medications
PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation
  • Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
  • Postmenopausal osteoporosis drugs market in Americas
  • Postmenopausal osteoporosis drugs market in EMEA
  • Postmenopausal osteoporosis drugs market in APAC
PART 12: Market drivers
  • Increase in older population
  • Growing prevalence of postmenopausal osteoporosis
  • Expected launch of promising pipeline molecules
  • High unmet medical needs
PART 13: Impact of drivers

PART 14: Market challenges
  • Multiple patent expiries
  • Low diagnosis rate
  • Nonadherence to treatment regimen
  • Drug reimbursement issues
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Awareness programs and initiatives
  • Emergence of novel agents
  • Emergence of combination therapies
PART 17: Vendor landscape
  • Competitive scenario
  • Market analysis 2015
  • Eli Lilly
  • Amgen
  • Merck
  • Novartis
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Prevalence of osteoporosis based on gender 2015
Exhibit 03: Interpretation of BMD results
Exhibit 04: Timeline for development of osteoporosis drugs
Exhibit 05: Key buying criteria for postmenopausal osteoporosis drugs
Exhibit 06: Pipeline portfolio: Postmenopausal osteoporosis
Exhibit 07: Global postmenopausal osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class
Exhibit 10: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class on basis of revenue 2015
Exhibit 11: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy
Exhibit 12: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy on basis of revenue 2015
Exhibit 13: Segmentation of global postmenopausal osteoporosis drugs market based on geography 2015
Exhibit 14: Global postmenopausal osteoporosis drugs market by geography 2015-2020 ($ billions)
Exhibit 15: Global postmenopausal osteoporosis drugs market by geography 2015-2020
Exhibit 16: Postmenopausal osteoporosis drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Postmenopausal osteoporosis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Postmenopausal osteoporosis drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global postmenopausal osteoporosis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Percentage share of women in age group of 60 years and older 2015
Exhibit 21: Percentage share of women in age group of 80 years and above 2015
Exhibit 22: Impact of drivers
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Revenue from sales of major drugs in global postmenopausal osteoporosis drugs market 2013-2015 ($ millions)
Exhibit 25: Eli Lilly: YoY revenue and growth rate of FORTEO 2015 ($ billions)
Exhibit 26: Eli Lilly: Geographical segmentation of FORTEO 2015
Exhibit 27: Eli Lilly: YoY revenue and growth rate of Evista 2015 ($ millions)
Exhibit 28: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 29: Eli Lilly: Key takeaways
Exhibit 30: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ millions)
Exhibit 31: Amgen: Geographical segmentation of Prolia 2015
Exhibit 32: Amgen: Key takeaways
Exhibit 33: Merck: YoY revenue and growth rate of Fosamax 2013-2015 ($ millions)
Exhibit 34: Merck: Key takeaways
Exhibit 35: Novartis: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • Deltanoid Pharmaceuticals
  • Novartis
  • Osteologix
  • Radius Health
  • Uni-Bio Science Group
  • MORE
New Report Released: - Global Postmenopausal Osteoporosis Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Postmenopausal Osteoporosis Drugs Market: Eli Lilly, Amgen, Merck, and Novartis.

Other Prominent Vendors in the market are: Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group, Upsher-Smith Laboratories, Watson Pharmaceuticals, and Zosano Pharma.

Commenting on the report, an analyst from the research team said: “A trend to watch in the postmenopausal osteoporosis drugs market is the emergence of novel agents. There have been encouraging developments in the postmenopausal osteoporosis drug pipeline. Novel agents may offer superior benefit-risk profiles and improved safety profiles compared with conventional treatment options. Many drugs have obtained approval while others are in different phases of development. For instance, drugs such as odanacatib (MK-0822) by Merck exert their pharmacological action by inhibiting the enzyme cathepsin K, which is primarily responsible for the degradation of the bone matrix by osteoclasts.”

According to the report, a key growth driver for this market is the growing prevalence of postmenopausal osteoporosis. The average life expectancy for women is estimated to be around 73 years, which increases the risk of developing postmenopausal osteoporosis. During menopause, the amount of estrogen in the body declines, resulting in osteoporosis. According to the World Health Organization (WHO), osteoporosis is second only to cardiovascular disease as a global healthcare problem. It is estimated that over 200 million people worldwide have this disease, and this number is increasing considerably. It is estimated that 30% of all the women in the postmenopausal stage have postmenopausal osteoporosis in the US and Europe.

Further, the report states that one challenge that could hinder market growth is the low diagnosis rate of postmenopausal osteoporosis. Referred to as a silent disease, the patient remains unaware of it until it has progressed to the higher stages.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Eli Lilly
- Amgen
- Merck
- Novartis
- Allergan
- Amgen Astellas Biopharm
- Deltanoid Pharmaceuticals
- Noven
- Novo Nordisk
- Osteologix
- Pfizer
- PhytoHealth
- Radius Health
- Tarsa Therapeutics
- UCB
- Uni-Bio Science Group
- Upsher-Smith Laboratories
- Watson Pharmaceuticals
- Zosano Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll